Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study